Rationalizing rules for immunotherapy combination trials: About time for precision immunotherapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36309827.
- Also identified by DOI 10.1002/cncr.34514.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immunotherapy has changed the landscape of cancer treatment. However, the benefit of immunotherapy is seen only in some cases, with most patients experiencing cancer progression despite treatment with immunotherapy. To overcome this, combination immunotherapy treatments are being studied. Herein, we propose for a precision-driven approach for patient selection to identify successful combinations of immunotherapy to improve outcomes for patients with cancer.
Medical subject headings
- Immunotherapy
- Neoplasms